Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | BL-M07D1 |
| Trade Name | |
| Synonyms | BLM07D1|BL M07D1 |
| Drug Descriptions |
BL-M07D1 is an antibody-drug conjugate (ADC) comprising the Erbb2 (Her2)-targeted monoclonal antibody trastuzumab linked to a topoisomerase I inhibitor (Ed-04), which potentially induces cell cycle arrest and apoptosis and inhibits tumor growth (Cancer Res (2023) 83 (7_Supplement): 2643). |
| DrugClasses | HER2 (ERBB2) Antibody 79 HER2 (ERBB2) Antibody-Drug Conjugate 35 |
| CAS Registry Number | NA |
| NCIT ID | C189821 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| BL-M07D1 | BL-M07D1 | 0 | 1 |